Ginkgo Bioworks Stock News

These biotech stocks are swinging for the fences. They may hit homers, they may strike out.

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly -

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago.

Ginkgo Bioworks (NYSE: DNA ) just reported first quarter results for 2023. Ginkgo Bioworks reported a loss per share of 11 cents.

Are these the best penny stocks to buy right now? Here's what's moving on Monday.

The bio-engineering companyexpects a sharp slowdown in revenue this year. Despite all of its partnerships, Ginkgo's business isn't overly diverse, suggesting it could have a hard time handling an econ

Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp decelerati

Ginkgo Bioworks still needs to prove its core business model. Ginkgo doesn't have any shortage of customers, and more are likely on the way.

Cathie Wood bought shares of Roku, Tesla, and Ginkgo Bioworks on Thursday. Roku and Tesla are beating the market this year, but Tesla fell sharply on Thursday after posting troublesome financial resul

Last year was a rough one for growth stocks, as investors shied away from risk in the face of rising interest rates. But in 2023, investors are once again on the hunt for companies with above-average

Here's what you need to know about making money with penny stocks during a market downtrend The post How to Navigate Penny Stock Downtrends, 3 Tips and Tricks appeared first on Penny Stocks to Buy, Pi

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attr

Coaxing cells to produce mRNA for therapeutic applications has been an unsuccessful endeavor so far. Miroslav Gasparek is on a mission to use synbio to change that.

Ginkgo Bioworks is improving its efficiency and building its clientele. Nonetheless, its coronavirus diagnostic revenue is falling and unlikely to recover.